Roche announced new data from the AVONELLE-X and SALWEEN studies of Vabysmo, presented at the 25th Euretina Congress. The AVONELLE-X study showed Vabysmo maintained disease control and durability over four years in nAMD patients. Nearly 80% of these patients were on extended dosing by the study's end. The SALWEEN study demonstrated clinically meaningful vision improvements in over 60% of patients with a difficult-to-treat nAMD subtype, polypoidal choroidal vasculopathy (PCV). In SALWEEN, over 60% of PCV patients showed no signs of damaging lesions. Vabysmo was also well tolerated with a consistent long-term safety profile in both studies. The SALWEEN study showed an 8.9 letter gain in visual acuity for PCV patients. More than 50% of SALWEEN participants were on extended five-month dosing after one year. Vabysmo is approved in over 100 countries for nAMD and diabetic macular edema. Over eight million doses of Vabysmo have been distributed globally since its initial US approval in 2022.